Protagonist Therapeutics Eulerpool Novinky

Protagonist Therapeutics Novinky o akciách

Protagonist Therapeutics sledujú mnohí novinári a investori po celom svete. Najaktuálnejšie správy Protagonist Therapeutics zhromažďujeme práve tu.

• 13. januára ·

  SeekingAlpha
  Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
• 6. januára ·

  Yahoo
  Protagonist Therapeutics Reports Granting of Inducement Awards
• 19. decembra ·

  Yahoo
  Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
• 9. decembra ·

  Yahoo
  Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
• 6. decembra ·

  Yahoo
  Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
• 29. novembra ·

  Yahoo
  Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
• 22. novembra ·

  Yahoo
  Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
• 21. novembra ·

  Yahoo
  Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
• 19. novembra ·

  Yahoo
  Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
• 18. novembra ·

  Yahoo
  Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor